Published in Br J Ophthalmol on January 01, 1996
How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol (2003) 3.07
Age-related macular degeneration--a genome scan in extended families. Am J Hum Genet (2003) 2.99
Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration. Am J Hum Genet (2003) 2.92
Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health (2006) 2.72
Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol (2006) 2.67
Do patients with age related maculopathy and cataract benefit from cataract surgery? Br J Ophthalmol (1998) 2.42
Therapeutic targets in age-related macular disease. J Clin Invest (2010) 1.68
CNV subtype in first eyes predicts severity of ARM in fellow eyes. Br J Ophthalmol (2003) 1.44
Vitamin E supplementation and macular degeneration: randomised controlled trial. BMJ (2002) 1.41
Visual impairment certification secondary to ARMD in Leeds, 2005-2010: is the incidence falling? Eye (Lond) (2012) 1.38
Perceived quality of health care in macular disease: a survey of members of the Macular Disease Society. Br J Ophthalmol (2002) 1.35
Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol (2002) 1.33
Enhanced low vision rehabilitation for people with age related macular degeneration: a randomised controlled trial. Br J Ophthalmol (2004) 1.26
Knowledge about cataract, glaucoma, and age related macular degeneration in the Hong Kong Chinese population. Br J Ophthalmol (2002) 1.17
Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. Hum Mutat (2011) 1.17
Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol (2004) 1.12
Genetic susceptibility to age related macular degeneration. J Med Genet (2000) 1.11
Reduced vision in older adults with age related macular degeneration interferes with ability to care for self and impairs role as carer. Br J Ophthalmol (2004) 1.07
Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol (2007) 1.04
Trends in blind registration in the adult population of the Republic of Ireland 1996-2003. Br J Ophthalmol (2006) 1.02
Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Mol Vis (2008) 0.98
The LOC387715 polymorphism, inflammatory markers, smoking, and age-related macular degeneration. A population-based case-control study. Ophthalmology (2007) 0.96
Lack of thrombospondin 1 and exacerbation of choroidal neovascularization. Arch Ophthalmol (2012) 0.94
Face recognition in age related macular degeneration: perceived disability, measured disability, and performance with a bioptic device. Br J Ophthalmol (2002) 0.94
Prevention of age-related macular degeneration. Int Ophthalmol (2010) 0.94
Development of choroidal neovascularization in rats with advanced intense cyclic light-induced retinal degeneration. Arch Ophthalmol (2010) 0.91
Age-related macular degeneration and recent developments: new hope for old eyes? Postgrad Med J (2007) 0.91
+Psychometric evaluation of the MacDQoL individualised measure of the impact of macular degeneration on quality of life. Health Qual Life Outcomes (2005) 0.89
Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol (2001) 0.89
Ophthalmic and visual profile of guide dog owners in Scotland. Br J Ophthalmol (1999) 0.88
Evaluation of the G protein coupled receptor-75 (GPR75) in age related macular degeneration. Br J Ophthalmol (2001) 0.88
Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. Int J Ophthalmol (2014) 0.88
Age-related macular disease. Br J Ophthalmol (1996) 0.85
Molecular genetic heterogeneity in autosomal dominant drusen. J Med Genet (2001) 0.83
Age-related macular degeneration. Postgrad Med J (1998) 0.83
Artificial means for restoring vision. BMJ (2005) 0.82
The genetics of complex ophthalmic disorders. Br J Ophthalmol (1996) 0.81
Geographic variation in the prevalence of macular disease among elderly medicare beneficiaries in Kansas. Am J Public Health (2005) 0.80
Progress and perspectives on the role of RPE cell inflammatory responses in the development of age-related macular degeneration. J Inflamm Res (2008) 0.80
Genetic basis of inherited macular dystrophies and implications for stem cell therapy. Stem Cells (2009) 0.78
Age-related macular disease: aetiology and clinical management. Community Eye Health (1999) 0.78
Effects of hydroquinone on retinal and vascular cells in vitro. Indian J Ophthalmol (2012) 0.77
An eye for discovery. J Clin Invest (2010) 0.77
Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration. Acta Ophthalmol (2016) 0.77
Differential effects of the estrogen receptor agonist estradiol on toxicity induced by enzymatically-derived or autoxidation-derived oxysterols in human ARPE-19 cells. Curr Eye Res (2013) 0.75
The long-term effects of visible light on the eye. Arch Ophthalmol (1992) 4.39
Epidemiological function of BD8 certification. Eye (Lond) (1993) 2.60
Blindness and partial sight in an elderly population. Br J Ophthalmol (1986) 2.39
Sibling correlations and segregation analysis of age-related maculopathy: the Beaver Dam Eye Study. Genet Epidemiol (1994) 2.39
Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol (1993) 3.42
Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye (Lond) (2010) 3.26
Deprivation and late presentation of glaucoma: case-control study. BMJ (2001) 2.86
The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess (2007) 2.27
Causes of blind certifications in England and Wales: April 1999-March 2000. Eye (Lond) (2007) 2.11
BD8 certification of visually impaired people. Br J Ophthalmol (1998) 1.96
Chronic glaucoma in northern Ghana--a retrospective study of 397 patients. Eye (Lond) (1990) 1.88
Risk factors for development of post-trabeculectomy endophthalmitis. Br J Ophthalmol (2000) 1.72
Who should see eye casualties?: a comparison of eye care in an accident and emergency department with a dedicated eye casualty. J Accid Emerg Med (1995) 1.56
Journals and the Internet. Use of the Internet for on line peer review must be explored further. BMJ (1997) 1.51
Time to look again at sight tests. BMJ (1997) 1.47
Surgical interventions for age-related cataract. Cochrane Database Syst Rev (2006) 1.41
Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev (2005) 1.41
What's in a name? New glaucoma drugs. Lancet (2006) 1.40
Risk factors for late presentation in chronic glaucoma. Invest Ophthalmol Vis Sci (1999) 1.36
Detection and prevention of treatable visual failure in general practice: room for improvement? Br J Gen Pract (1994) 1.28
Registration of blind and partially sighted people. Br J Ophthalmol (1994) 1.23
Retinal vascular network architecture in low-birth-weight men. J Hypertens (1997) 1.15
Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol (2005) 1.09
Screening for prevention of optic nerve damage due to chronic open angle glaucoma. Cochrane Database Syst Rev (2006) 1.08
Community ophthalmology pilot study. Eye (Lond) (1993) 1.06
Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev (2007) 1.04
Evaluation of ophthalmoscopy by nonophthalmologists in diagnosing chronic glaucoma in West Africa. Eye (Lond) (1989) 1.03
Retrospective analysis of risk factors for late presentation of chronic glaucoma. Br J Ophthalmol (1999) 1.02
Age-related Bruch's membrane change: a clinical study of the relative role of heredity and environment. Br J Ophthalmol (1993) 0.96
The Peterborough scheme for community specialist optometrists in glaucoma: a feasibility study. Eye (Lond) (2010) 0.96
Cataract surgery--quantity and quality. Br J Ophthalmol (1999) 0.95
Essential fatty acids, plasma cholesterol, and fat-soluble vitamins in subjects with age-related maculopathy and matched control subjects. Am J Clin Nutr (1993) 0.93
Hypertensive retinopathy in Afro-Caribbeans and Europeans. Prevalence and risk factor relationships. Hypertension (1995) 0.92
Ivermectin for onchocercal eye disease (river blindness). Cochrane Database Syst Rev (2001) 0.89
The primary treatment trial: changes in the visual field analysis by computer-assisted perimetry. Eye (Lond) (1994) 0.88
Visual acuity and its relationship to early growth, eye disease, and aging in north Hertfordshire. Ophthalmic Epidemiol (1998) 0.87
Causes of certifications for severe sight impairment (blind) and sight impairment (partial sight) in children in England and Wales. Br J Ophthalmol (2013) 0.86
Why involve consumers in eye health research? Eye (Lond) (2011) 0.86
The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003. Br J Ophthalmol (2006) 0.85
Appropriate technology for cataract surgery. Lancet (1998) 0.85
Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev (2001) 0.84
Nutrition and the epidemiology of cataract and age-related maculopathy. Eur J Clin Nutr (1994) 0.83
Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994-2005. Eye (Lond) (2008) 0.81
A new health technology: where is the consensus on a clinically worthwhile benefit? Eye (Lond) (2002) 0.80
Do selective topical beta antagonists for glaucoma have respiratory side effects? Br J Ophthalmol (2004) 0.80
Introduction of photodynamic therapy for the treatment of neovascular age-related macular degeneration: tracking a moving target. Eye (Lond) (2003) 0.80
Evidence based medicine, the Cochrane Collaboration, and the CONSORT statement. Br J Ophthalmol (1998) 0.78
Brain natriuretic peptide: identification of a second natriuretic peptide in human aqueous humour. Br J Ophthalmol (1998) 0.76
Prophylactic laser treatment appears to promote choroidal neovascularisation in high-risk ARM: results of an interim analysis. Eye (Lond) (2003) 0.76
Is one trial enough? Br J Ophthalmol (2005) 0.75
Impaired motion sensitivity as a predictor of subsequent field loss in glaucoma suspects: the Roscommon Glaucoma Study. Br J Ophthalmol (1998) 0.75
The NHS Act of 1951; is it time to re-act? Eye (Lond) (2013) 0.75
Treatment of raised intraocular pressure and prevention of glaucoma. BMJ (2003) 0.75
Prevention of blindness by screening for diabetic retinopathy. BMJ (1989) 0.75
Needs and demands for ophthalmology services. BMJ (1992) 0.75
Cost effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom using a decision-analytic health economic model. Eye (Lond) (2009) 0.75
Blood pressure and glaucoma. Br J Ophthalmol (1996) 0.75
Universal neonatal screening; falling on deaf ears? Ir Med J (2008) 0.75
Cochrane eye and vision group. Br J Ophthalmol (2011) 0.75
The impact of influenza A H1N1 on paediatric ear, nose and throat services. Ir Med J (2011) 0.75
Cochrane Eyes and Vision Group (CEVG). Br J Ophthalmol (2010) 0.75
CT diagnosis of scleral rupture. Eye (Lond) (1987) 0.75
Glaucoma and race. Lancet (1989) 0.75